News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oxford Immunotec (OXFD) Reports Second Quarter 2017 Financial Results



8/1/2017 9:21:05 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
  • Second quarter revenue of $26.1 million, an increase of 36% compared to prior year period
  • Continued growth from both the Tuberculosis and Tick-borne disease franchises
  • Successful negotiation of a settlement with Statens Serum Institut which will result in substantial future gross margin improvement
  • Raising revenue guidance for the full year from $102-$105 million to $103-$106 million

OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced second quarter 2017 financial results.

“We delivered a strong second quarter with revenue growth that exceeded the top end of our guidance range,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “As we continue our evolution from a single-product company to a multi-product company, we are pleased to see solid growth in our core tuberculosis (TB) business as well as a strong contribution from our accelerating tick-borne disease franchise.”

By revenue type, total revenues were, in millions:


Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES